Results 231 to 240 of about 211,411 (286)

Voclosporin ameliorates proteinuria in a model of non-inflammatory glomerular disease. [PDF]

BMC Nephrol
Kamigaki Y, Dougherty JA, Waller AP, Wolfgang KJ, Rehaume LM, Cross JL, Zhou S, Biederman LE, Stevenson ZS, Abdelghani E, Kerlin BA, Smoyer WE.   +11 more
europepmc   +1 more source

Testing the Broad Definition of Pre‐Eclampsia: Should Chronic Hypertension With Fetal Growth Restriction Be Included?

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
Peter von Dadelszen, Terry Lee, Joel Singer, Laura A. Magee, For the CHIPS Study Group   +4 more
wiley   +1 more source

Improvement of Health‐Related Quality of Life and Mental Health After Unilateral Adrenalectomy for Primary Aldosteronism

Clinical Endocrinology, EarlyView.
ABSTRACT Background Primary aldosteronism (PA) has been linked with reduced health‐related quality of life (QoL) and increased prevalence of anxiety and depression. While most studies compared patients with PA to healthy subjects, this study focused on comparison with hypertensive patients without PA to identify PA‐specific effects.
Sybille Fuld, Christian Adolf, Georgiana Constantinescu, Manuel Schulze, Denise Brüdgam, Carmina T. Fuss, Hanna Remde, Lydia Kürzinger, Sven Gruber, Jun Yang, Amy Kang, Martin Reincke, Felix Beuschlein, Graeme Eisenhofer, Jacques W. M. Lenders, Christina Pamporaki   +15 more
wiley   +1 more source

Lower proteinuria is better for patients with IgA nephropathy: a systematic review. [PDF]

Front Nephrol
Shah A, Maski M, Egbuna O, Longstaff W, Stricker-Shaver J, Barber B.   +5 more
europepmc   +1 more source

Incidence, Progression and Determinants of Diabetic Retinopathy in Type 2 Diabetes in Australasia: A Systematic Review and Meta‐Analysis

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Current evidence on incidence and progression rate of diabetic retinopathy reveals disparities across Australasia, and no pooled estimates are available to guide region‐wide planning. This review and meta‐analysis assesses the overall incidence, determinants and progression of diabetic retinopathy in Australasia.
Getasew Alemu Mersha, Mesert Derbew Molla, Ranjay Chakraborty, Georgia Kaidonis, Stewart Lake, Jamie Craig, José Estevez   +6 more
wiley   +1 more source

Outcomes and predictors of kidney failure in elderly patients with biopsy-proven IgA nephropathy. [PDF]

Ren Fail
Ștefan G, Petre N, Zugravu A, Stancu S.
europepmc   +1 more source

Emerging Role of Ferroptosis in Diabetes and Associated Complications: When Metabolic Dysregulation Meets Cell Death

Cell Proliferation, EarlyView.
This study identifies ferroptosis as a key driver of diabetes and its complications via iron metabolism and lipid peroxidation, elucidates organelle interactions underlying cell vulnerability, and provides insights for targeted therapies against metabolic disorders.
Zheng Wang, Ying Zhang, Yue Xu, Mengyuan Yang, Yuan Wei, Yuan Li, Tongyue Yang, Xu Wang, Chaona Yang, Qi Feng, Guolan Xing   +10 more
wiley   +1 more source

Systemic Lupus Erythematosus With IgA Nephropathy: Challenges in Diagnosis and Management. [PDF]

Am J Case Rep
Shah M, Malik F, Shah M, Patel MD, Pathakjee R, Pandya S.   +5 more
europepmc   +1 more source

Association between diabetes and in‐hospital outcomes in patients with metabolic dysfunction‐associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study

Diabetic Medicine, EarlyView.
In a nationwide cohort of 10,614 patients with metabolic dysfunction–associated steatotic liver disease (MASLD) hospitalized for cardiovascular disease (CVD), diabetes was present in 4550 patients (43%) and was independently associated with higher in‐hospital mortality and cardiovascular complications.
Soichi Komaki, Michikazu Nakai, Yunosuke Matsuura, Kinuko Yamamoto, Hiroki Tanaka, Yuri Komaki, Masashi Yamaguchi, Kohei Moribayashi, Takeshi Ideguchi, Hiroshi Kawakami, Toshihiro Tsuruda, Koichi Kaikita   +11 more
wiley   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source